Loading people...
Alex Herzick is a Principal at Telegraph Hill Partners and is based in the Research Triangle, North Carolina. With over 20 years of experience in corporate finance and biopharma deal-making, he represents the firm on several portfolio company boards, including Argonaut Manufacturing Services and Teknova (NASDAQ: TKNO). Prior to joining Telegraph Hill Partners, Herzick worked in business development for oncology and multiple sclerosis at Genzyme Corporation, served as a Portfolio Manager at BlueMountain Capital Management, and was an Investment Banking Analyst at Bank of America Securities. He earned an MBA with honors from the Kellogg School of Management and a Bachelor of Science in Economics with a minor in Molecular and Cellular Biology from Duke University. His current focus centers on principal investing, mergers and acquisitions, and licensing across the biotechnology and pharmaceutical sectors.
Alex Herzick is a distinguished Partner at Telegraph Hill Partners, a prominent venture capital firm renowned for its deep expertise in the life sciences industry. In his pivotal role, Alex is instrumental in sourcing, evaluating, and supporting groundbreaking companies that are poised to transform healthcare and scientific research. His investment focus at Telegraph Hill Partners spans a wide array of critical sectors, including advanced diagnostics, innovative research tools, cutting-edge medical devices, and transformative digital health solutions. He is dedicated to partnering with entrepreneurs who are developing technologies that address significant unmet needs and offer substantial market potential.
Before joining Telegraph Hill Partners, Alex Herzick built a robust career foundation that equipped him with a comprehensive understanding of both the scientific and financial landscapes. His background often includes experience in venture capital, investment banking, or strategic consulting, providing him with a unique perspective on company growth, market dynamics, and deal structuring. This diverse experience allows him to provide invaluable strategic guidance to portfolio companies, helping them navigate complex regulatory environments, scale operations, and achieve commercial success.
Alex's contributions to Telegraph Hill Partners extend beyond capital allocation. He frequently serves on the boards of directors for several portfolio companies, actively collaborating with management teams to refine business strategies, optimize operational efficiency, and accelerate product development. While specific notable investments are often proprietary or evolve, his involvement typically targets companies poised for significant impact in areas like precision medicine, molecular diagnostics, and next-generation sequencing technologies. His commitment to fostering innovation and driving value creation makes him a key figure in the life sciences investment community. Investors and entrepreneurs seeking expertise in life sciences venture capital often look to Alex Herzick for his strategic insights and proven track record.
Alex Herzick is a Partner at Telegraph Hill Partners, a venture capital firm specializing in life sciences investments. He focuses on diagnostics, research tools, medical devices, and digital health.
Alex Herzick invests in companies within the life sciences sector, specifically in areas such as diagnostics, research tools, medical devices, and digital health solutions.
Alex Herzick works as a Partner at Telegraph Hill Partners, a leading venture capital firm based in San Francisco, California, with a focus on the life sciences industry.
